EPO Patents = 2

Forward Citations = 14

Loading Chart...

2 inventors (with patents filed for the assignee):

Robert A Shalwitz (6 out of 33 patents)

Anna Kotsakis Ruehlmann (2 out of 2 patents)

6 patents: Sort by Forward Citations

1. 12370209 - Methods for the use of 5'-adenosine diphosphate ribose (ADPR) (2025-07-29),

2. 12233083 - Methods for the use of 5'-adenosine diphosphate ribose (ADPR) (2025-02-25),

3. 11857561 - Methods for the use of 5′-adenosine diphosphate ribose (ADPR) (2024-01-02),

4. 11793826 - Methods for the use of 5'-adenosine diphosphate ribose (ADPR) (2023-10-24),

5. 11110112 - Methods for the use of 5'-adenosine diphosphate ribose (ADPR) (2021-09-07),

6. 10946034 - Methods for the use of 5'-adenosine diphosphate ribose (ADPR) (2021-03-16),

Invirsa, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of ocular diseases. Their flagship product is a novel medication for the treatment of viral and inflammatory eye conditions. With a strong pipeline of cutting-edge drugs, Invirsa is committed to advancing the field of ophthalmology and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

6 Patents

#116 in Columbus, OH

#1,711 in Ohio

#43,751 in US

Columbus, OH, United States of America

Invirsa, Inc.

Forward Citations = 14

2 inventors:

Robert A Shalwitz (6 out of 33 patents)

Anna Kotsakis Ruehlmann (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com